BeiGene bags a stag­ger­ing $903M IPO on the HKEX — and still man­ages to spark some ner­vous fret­ting

BeiGene’s sec­ondary IPO on the Hong Kong ex­change says a lot about the sky-high ex­pec­ta­tions of the biotechs lin­ing up to cash in there un­der more lib­er­al list­ing rules.

The biotech raised $903 mil­lion, and that was on the low end of the range.

HKEX is com­mand­ing at­ten­tion from bio­phar­ma for a sec­ond day with the news that BeiGene’s IPO fell shy of the $1 bil­lion ceil­ing it was reach­ing for.

BeiGene’s sec­ondary IPO, as re­port­ed by Reuters, comes as biotechs join the queue for a bo­nan­za of wind­fall rais­es in Hong Kong. The first of them, As­cle­tis Phar­ma, be­gan trad­ing Wednes­day af­ter pock­et­ing $400 mil­lion and closed flat.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER